4G Clinical has announced the launch of 4C Supply, a clinical supply optimization software powered by Natural Language Processing (NLP). The new product addresses the increased pressures on clinical supply professionals to continuously adapt to new trial information as protocol complexity continues to rise.
Clinical supply professionals are tasked with assessing the impact of protocol revisions, sometimes as soon as the initial protocol version is approved. Supply impact assessments are critical, and time sensitive, and traditional supply software solutions are slow to respond and challenging to interpret without extensive knowledge of statistical algorithms.
4C Supply utilizes Natural Language Processing (NLP) to turn study parameters from plain English into detailed forecasts, allowing supply managers to modify supply models as frequently as needed without effort, with full transparency into inputs and a direct correlation to its outputs.
"Over the past year, 4G Clinical has collaborated with bio/pharma clinical supply professionals to verify the industry need for an improved solution and pressure test the development of 4C Supply," says Jan Pieter Kappelle, Vice President of Strategy at 4G Clinical. "We have been incredibly fortunate to have such a dedicated group of advisors and we are excited to announce the launch of what we believe is a game-changer for clinical supply professionals."
"To be involved in the creation of an innovative clinical supply software solution from the onset has been a valued opportunity for us," says Darrin Sloan, Senior Manager, Clinical Supply at Eisai. "We are excited for the commercial launch of 4C Supply and the benefit it will bring to supply managers across the industry."
In addition to early collaborators, 4G Clinical has also extended early access to 4C Supply to several of their Prancer RTSM customers.
"4G Clinical's RTSM has completely changed the way we have built studies and managed our supplies," says Karen McNamara, Senior Director, Product Development at Infinity Pharmaceuticals. "We are incredibly excited to be an early-adopter of 4C Supply and look forward to our continued partnership with 4G Clinical."
"The launch of 4C Supply is a testament to 4G Clinical's commitment to accelerating clinical trials," says David Kelleher, CEO of 4G Clinical. "Managing the complexity of clinical supply in a more efficient and intuitive manner better enables patients to receive the right medication at exactly the right time."
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.